Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat...

書目詳細資料
Main Authors:	Peyrin-Biroulet, L, Sandborn, W, Sands, B, Reinisch, W, Bemelman, W, Bryant, R, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, P, Loftus, E, Marteau, P, Munkholm, P, Murdoch, T, Ordás, I, Panaccione, R, Riddell, R, Ruel, J, Rubin, D, Samaan, M, Siegel, C, Silverberg, MS, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, J
格式:	Journal article
語言:	English
出版:	Nature Publishing Group 2015

相似書籍

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
由: Sandborn, W, et al.
出版: (2016)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
由: Peyrin-Biroulet, L, et al.
出版: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
由: Danese, S, et al.
出版: (2015)

Development of an index to define overall disease severity in IBD
由: Siegel, C, et al.
出版: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
由: D'Haens, G, et al.
出版: (2009)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
由: Remo Panaccione, et al.
出版: (2015-12-01)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
由: Jairath, V, et al.
出版: (2016)

Development of the Crohn's disease digestive damage score, the Lemann score.
由: Pariente, B, et al.
出版: (2011)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
由: Reinisch, W, et al.
出版: (2018)

Evolving concepts in phases I and II drug development for Crohn's Disease
由: Jairath, V, et al.
出版: (2016)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
由: Khanna, R, et al.
出版: (2023)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
由: Travis, S, et al.
出版: (2013)

Biosimilars in IBD: hope or expectation?
由: Gecse, K, et al.
出版: (2013)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
由: Vuitton, L, et al.
出版: (2017)

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
由: Clark, M, et al.
出版: (2007)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
由: Gasche, C, et al.
出版: (2000)

Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
由: Travis, S, et al.
出版: (2013)

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].
由: Travis, S, et al.
出版: (2015)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
由: Panaccione, R, et al.
出版: (2019)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
由: Travis, S, et al.
出版: (2012)

Review article: defining remission in ulcerative colitis.
由: Travis, S, et al.
出版: (2011)

European evidence-based Consensus on the management of ulcerative colitis: Current management.
由: Travis, S, et al.
出版: (2008)

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
由: Laurent Peyrin-Biroulet, et al.
出版: (2024-01-01)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
由: Sandborn, W, et al.
出版: (2015)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
由: Colombel, J, et al.
出版: (2017)

CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease
由: Ma, C, et al.
出版: (2022)

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
由: Travis, S, et al.
出版: (2017)

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
由: Travis, S, et al.
出版: (2017)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
由: D'Haens, G, et al.
出版: (2011)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
由: Van Assche, G, et al.
出版: (2011)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
由: Travis, S, et al.
出版: (2014)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
由: Lichtenstein, G, et al.
出版: (2015)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
由: D'Haens, G, et al.
出版: (2018)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
由: Yzet, C, et al.
出版: (2019)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
由: Gottlieb, K, et al.
出版: (2015)

The real-world global use of patient-reported outcomes for the care of patients with inflammatory bowel disease
由: Horrigan, JM, et al.
出版: (2023)

Benzimidazoles promote anti-TNF mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model
由: Wildenberg, M, et al.
出版: (2017)

Antieosinophil Therapeutics
由: Straumann, A, et al.
出版: (2013)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
由: Samaan, MA, et al.
出版: (2018)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
由: Travis, S, et al.
出版: (2017)